Pharmaceutical Business Review
Anonymous User | Login

Alcon Signs Agreement With AstraZeneca On Eye Drug Development

Published: 22-Jul-2009

Alcon and AstraZeneca are targeting development of drugs to treat sight-threatening diseases

Alcon has entered into a five-year collaborative research agreement with AstraZeneca, for the exclusive ophthalmic discovery and potential development rights to AstraZeneca’s compound library.

Reportedly, the two companies are targeting development of drugs to treat sight-threatening conditions such as glaucoma, wet and dry age-related macular degeneration and other retinal diseases, as well as ocular allergy, dry eye and other inflammatory eye conditions.

Under the terms of the agreement, Alcon obtains immediate access to thousands of AstraZeneca compounds in a variety of drug classes. AstraZeneca will hand over development and regulatory documentation associated with each compound as relevant to ophthalmology.

Additionally, Alcon will perform and fund all research and development activities to move selected compounds forward.

In addition, the agreement provides for individual license agreements to be negotiated on a case by case basis for any compound that moves into clinical development, including regulatory milestone payments and royalties on product sales.

Sabri Markabi, senior vice president of research and development and chief medical officer of Alcon, said: “Our agreement with AstraZeneca stems from our strategy of enhanced access to sources of technologies and compounds through partnership with leading biomedical research organizations. The combination of AstraZeneca’s broad capabilities in discovery and Alcon’s scientific expertise in eye disease provides potential for therapies that fulfil unmet medical needs in ophthalmology.”

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Almac

Drug Development Solutions ...

STARLIMS

Benefits for Life Science Labs ...

Parenteral Drug Association (PDA)

Pharmaceutical Information and Education Services ...

Burkert Fluid Control Systems

Fluid and Gas Control Systems ...

IMCOR

LIMS and Laboratory Informatics Consultancy ...

Umicore Precious Metals Chemistry

Chemicals and Catalysts for Industrial Applications ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

CaseBase Management

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

SafetyBase Interchange

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

ClinicalBase Trial

BaseCon was established in 1999 to support the pharmaceutical sector with innovative IT so ...

Reliable Prediction of White Plasma Levels

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Kinetics and Metabolism

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Drug Safety Evaluation

Our kinetics & metabolism experts can help you select and further develop your candidate d ...

Related Companies

Bausch & Lomb Incorporated

Bausch & Lomb Incorporated (Bausch & Lomb) is a eye health company, engaged in manufact ...

CIBA Vision Corporation

CIBA Vision Corporation (CIBA) is engaged in the manufacture, research and development ...

CooperVision, Inc.

CooperVision, Inc. (CVI) is a medical device company and a subsidiary of The Cooper Com ...

Essilor International

Essilor International (Essilor) is a leading producer of optical products. The company ...

ISTA Pharmaceuticals, Inc.

ISTA Pharmaceuticals, Inc. (ISTA) is a specialty pharmaceutical company engaged in deve ...

Suppliers Product News

Almac Completes Phase One of Its Expansion Plan to Pharma Services Facilities

New $15m facility will "meet growing business need for its integrated product development and commercial services."

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address